An Open-Label, Multicenter, First-in-Human, Phase 1 Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ES009 administered intravenously to subjects with advanced solid tumors.
Molecular cytogenetics and development of St-chromosome-specific molecular markers of novel stripe rust resistant wheat-Thinopyrum intermedium and wheat-Thinopyrum ponticum substitution lines.
Article
作者: Siwen Wang ; Changyou Wang ; Xianbo Feng ; Jixin Zhao ; Pingchuan Deng ; Yajuan Wang ; Hong Zhang ; Xinlun Liu ; Tingdong Li ; Chunhuan Chen ; Baotong Wang ; Wanquan Ji
BACKGROUND:
Owing to their excellent resistance to abiotic and biotic stress, Thinopyrum intermedium (2n = 6x = 42, JJJsJsStSt) and Th. ponticum (2n = 10x = 70) are both widely utilized in wheat germplasm innovation programs. Disomic substitution lines (DSLs) carrying one pair of alien chromosomes are valuable bridge materials for transmission of novel genes, fluorescence in situ hybridization (FISH) karyotype construction and specific molecular marker development.
RESULTS:
Six wheat-Thinopyrum DSLs derived from crosses between Abbondanza nullisomic lines (2n = 40) and two octoploid Trititrigia lines (2n = 8x = 56), were characterized by sequential FISH-genome in situ hybridization (GISH), multicolor GISH (mc-GISH), and an analysis of the wheat 15 K SNP array combined with molecular marker selection. ES-9 (DS2St (2A)) and ES-10 (DS3St (3D)) are wheat-Th. ponticum DSLs, while ES-23 (DS2St (2A)), ES-24 (DS3St (3D)), ES-25(DS2St (2B)), and ES-26 (DS2St (2D)) are wheat-Th. intermedium DSLs. ES-9, ES-23, ES-25 and ES-26 conferred high thousand-kernel weight and stripe rust resistance at adult stages, while ES-10 and ES-24 were highly resistant to stripe rust at all stages. Furthermore, cytological analysis showed that the alien chromosomes belonging to the same homoeologous group (2 or 3) derived from different donors carried the same FISH karyotype and could form a bivalent. Based on specific-locus amplified fragment sequencing (SLAF-seq), two 2St-chromosome-specific markers (PTH-005 and PTH-013) and two 3St-chromosome-specific markers (PTH-113 and PTH-135) were developed.
CONCLUSIONS:
The six wheat-Thinopyrum DSLs conferring stripe rust resistance can be used as bridging parents for transmission of valuable resistance genes. The utility of PTH-113 and PTH-135 in a BC1F2 population showed that the newly developed markers could be useful tools for efficient identification of St chromosomes in a common wheat background.
1989-01-01·Vox sanguinis4区 · 医学
Stability of murine monoclonal anti-A, anti-B and anti-A,B ABO grouping reagents and a multi-centre evaluation of their performance in routine use.
4区 · 医学
Article
作者: A McGowan ; A Tod ; A Chirnside ; C Green ; K McColl ; S Moore ; P L Yap ; D B McClelland ; M C McCann ; L R Micklem
We have previously reported the production of 3 murine monoclonal reagents for ABO typing (designated ES-9, ES-4 and ES-15). This study presents results of tests of stability of these 3 reagents, together with a fourth murine monoclonal antibody (LM103/107). In addition, data are also presented from a multi-centre evaluation of the performance of the murine monoclonal reagents in routine ABO typing of both donors and patients using a wide variety of techniques, both manual and automated. The potency and stability of the 4 monoclonal antibody based reagents is compared with a broad selection of monoclonal and polyclonal ABO typing reagents. The reagents used for comparison were produced by European and United States manufacturers in both the public and private sector and are widely used in routine ABO typing. The Scottish monoclonal reagents have been used successfully to ABO type over 500,000 blood samples in 7 centres within the UK, with no discrepant results.
1988-10-01·Zhongguo Yixue Kexueyuan Xuebao
Genetic monitoring of inbred rats by electrophoresis technique
Article
作者: Shi, Shundi
Fifteen rat protein product gene markers including Amy-1, Cat, Es-1, Es-2, Es-3, Es-4, Es-6, Es-7, Es-8, Es-9, Es-10, Es-12, Gc, Hbb, Svp-1 were examined by electrophoresis. The electrophoretic genetic profiles of 5 inbred rats (F344/ Ola, F344/N, WKY/Ola, LOU/cN, SHR/Ola) were described to provide a genetic basis and quality control for inbred rat.
SHANGHAI & SUZHOU, China & GERMANTOWN, Md.--(BUSINESS WIRE)-- Elpiscience Biopharma (“Elpiscience”), a clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation cancer immunotherapies, announced today that the first patient has been dosed in a Phase 1 clinical trial of its anti-LILRB2 monoclonal antibody ES009 in Australia. The objective of the trial is to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity.
LILRB2, also known as ILT4, is an inhibitory receptor widely expressed on the surface of myeloid cells that also contributes significantly to immune suppression in the tumor microenvironment (TME). ES009 specifically binds to a unique epitope on human LILRB2 and potently blocks LILRB2 binding to multiple ligands. By blocking LILRB2-mediated inhibitory signaling, ES009 can reprogram myeloid cells from anti-inflammatory phenotype into pro-inflammatory phenotype, and reinvigorate T cell functionalities. ES009 has demonstrated exceptional potential to reverse immune suppression in the TME and promote anti-tumor immunity in preclinical studies.
“LILRB2 is a key immune checkpoint for tumor immunotherapy whose suppression of immune response is proved as one mechanism of anti-PD(L)1 resistance. With a keen interest in revolutionizing therapies for cancer patients non-responsive or resistant to PD(L)1 treatment, we developed ES009 which has shown best-in-class potential. We believe in the power of enhanced innate immunity in treating cancer and have developed a highly differentiated myeloid cell focused therapeutics portfolio. We will work relentlessly to bring these highly promising therapies to cancer patients with unmet medical needs,” said Dr. Hongtao Lu, Co-founder and CSO of Elpiscience.
About Elpiscience
Elpiscience is a clinical-stage biopharmaceutical company dedicated to developing life-changing immuno-oncology therapies for cancer patients worldwide. The company’s innovative approach is focused on removing immunosuppressive factors in the tumor microenvironment, by targeting the adenosine pathway and myeloid checkpoints. A pipeline of novel molecules has been developed using its proprietary platforms including a powerful Bispecific Macrophage Engager (BiME®) technology that connects and activates macrophages for solid tumor killing without causing cytokine storms.
For more information, please visit: